Subscribe Subscribe   Find us on Twitter Follow POL on Twitter  



More Merck

In a piece in the National Law Journal, Peter Geier notes that Peter Bicks and John Brenner, litigators with no connection to the Vioxx case, both seem to agree that Merck's strategy-- continuing to address the cases one-at-a-time-- appears to be working, and that the recent verdict in McDarby was not as damaging as one might think. But as plaintiff's lawyer Brian Blevins observes in the same piece, Merck's stock price suffers with each plaintiff win. How long, Blevins wants to know, before it stops making economic sense to fight rather than settle? Kind of a grim question.



Isaac Gorodetski
Project Manager,
Center for Legal Policy at the
Manhattan Institute

Katherine Lazarski
Press Officer,
Manhattan Institute


Published by the Manhattan Institute

The Manhattan Insitute's Center for Legal Policy.